"Designing Growth Strategies is in our DNA"
Cloning is the procedure of creating genetically identical individuals of an organism either naturally or artificially. Mutagenesis is a progression by which the genetic information of an organism is changed, resulting in a mutation. Mutagenesis is performed in laboratory settings where the mutations in the DNA are engineered deliberately for the production of mutant proteins and genes or strains of an organism.
Cloning and mutagenesis are one of the most potent techniques developed to study the structure/function relationships of proteins, used to verify the effect of the mutation, both in vitro and in vivo. The global cloning & mutagenesis market growth is anticipated due to the increasing application of cloning in various genetic applications such as reproductive cloning.
To gain extensive insights into the market, Request for Customization
New product launches in the cloning and mutagenesis market are also expected to contribute positively to the global cloning & mutagenesis market growth. In October 2018, DNA DIAGNOSTIC A/S announced the launch of Infant 3, a PCR test kit for cronobacter spp. (Enterobacter sakazakii), Enterobacteriaceae, and salmonella in infant formula-related products.
The rising prevalence of chronic and genetic diseases and increased demand for personalized medicine are some of the major factors expected to drive the global cloning and mutagenesis market growth. The rise in the investment for research and development for the treatment of genetic disorders and other diseases such as HIV and cancer are some of the factors increasing demand for cloning and mutagenesis technologies.
This is of one of the major factors expected to drive the global cloning and mutagenesis market growth. Furthermore, increased funding by the government organization for medical research, rising biotechnology industries globally, and expanded strategic collaborations are some of the factors anticipated to drive the global cloning and mutagenesis market growth.
The factor that is expected to inhibit the global cloning and mutagenesis growth is the high cost of the kits, ethical issues surrounding the terminology in various countries, and lack of accuracy in methods of cloning and mutagenesis.
Some of the major companies that are present in the global cloning & mutagenesis market report include Thermo Fisher Scientific, Takara Bio Inc., Genomax Technologies Pte Ltd., GENEWIZ Inc., Agilent Technologies, Inc., Jena Bioscience GmbH, Transgen Biotech Co., LTD, New England Biolabs, abm Inc., GenScript, Merck KGaA, EZBioscience, and others.
SEGMENTATION | DETAILS |
By Technique | · Blunt End Cloning · Topo PCR Cloning · Seamless Cloning · Site-Directed Mutagenesis · Others |
By Product | · Cloning Kits · Mutagenesis Kits |
By End User | · Academic & Research Institutes · Biotechnology Companies · Others |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa) |
As per the current cloning & mutagenesis market trends, cloning kits in the product segment is projected to hold a considerable share of the global cloning & mutagenesis market due to higher adoption of cloning kits in research & development of different diseases due to higher investments in these activities.
Among the regions, North America is expected to dominate the global cloning and mutagenesis market in the forecast period. High investment in the research and development, increasing investment in biotechnology companies, more investment towards the development of the stem cell and cancer cell studies are factors expected to drive the growth of the cloning and mutagenesis market in North America region. Asia Pacific is anticipated to grow at a significant CAGR during the forecast period, owing to rising healthcare expenditure, increasing investment in biotechnology companies, increasing prevalence of the chronic diseases and adoption of personalized medicine by the patient pool in the region. Additionally, cloning & mutagenesis market in Middle East and Africa is in the nascent stage; however, unmet needs for cloning & mutagenesis is expected to drive the market growth in this region.
US +1 833 909 2966 ( Toll Free )